Key result
Ranolazine is a promising late sodium channel inhibitor in development that is likely to become standard therapy for chronic stable angina.
Ranolazine represents a promising therapeutic option for patients with chronic stable angina who remain symptomatic despite conventional therapy.
May support adjunctive use in refractory angina; leaves open definitive role pending randomized trials.
Chronic stable angina is common and is a difficult-to-manage problem when patients begin to fail conventional therapy especially when maximal revascularization has been provided. The most promising agent in development is ranolazine, a late sodium channel inhibitor and partial fatty oxidation inhibitor which has unique and desirable anti-ischemic and electrophysiologic properties. This agent is likely to become standard therapy for chronic stable angina and may play a future role in the management of acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Peter A. McCullough (2006) conducted a review in Chronic stable angina. Ranolazine was evaluated. Ranolazine is a promising late sodium channel inhibitor in development that is likely to become standard therapy for chronic stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: